Scholars Central

Conference abstractPublished 15 Apr 2014

Antibody-proteases as novel biomarkers and highly informative molecular tools to predict and to prevent demyelination

Authors: Sergey Suchkov, Noel Rose, Aleks Gabibov

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

P roteolytic Abs ( Ab-proteases ) are multivalent immunoglobulins (Igs) endowed with a capacity to degrade the antigenic (Ag) substrate. Anti-MBP autoAbs from MS patients and mice with EAE exhibited specific proteolytic cleavage of MBP The activity of the Ab-proteases markedly differs between: (i) MS patients and healthy controls; (ii) different clinical MS courses; (iii) EDSS scales of demyelination to correlate with the disability of MS patients to predict transformation prior to changes of the clinical course, i.e., changing of a remitting type (moderate one) into the secondary progradient type (aggressive one) prior to changing in a pattern of the clinical manifestations. The sequence-specificity of Ab-proteases demonstrates five sites of preferential proteolysis to be located within MBP. Those sites are located within the immunodominant regions; and two of them falling inside the sequence covering a 81-103 peptide segment and its 82-98 subsegment as well, with the highest encephalitogenic properties both to act as a specific inducer of EAE and to be attacked by the Ab-proteases very often in MS patients with the most severe (progradient) clinical courses. Sites localized within 43-68 and 146-170 whilst being less immunogenic happened to be EAE inducers very rare but were shown to be attacked by Ab-proteases very often in MS patients with moderate (remission-type) type. The activity of Ab- proteases was first registered at the subclinical stages 1-2 years prior to the clinical illness. About 24% of the direct MS-related relatives were seropositive for low-active Ab-proteases from which 38% established were demonstrating a stable growth of the activity. Moreover, we see also low-active Ab-proteases (to target 43-68 and 146-170 sites) in persons at MS-related risks (at the subclinical stages), and primary MRT manifestations observed were coincided with the mid-level activity. And registration in the evolution of highly immunogenic Ab-proteases to attack 81-103 and 82-98 sites predominantly would illustrate either risks of transformation of subclinical stages into clinical ones, or risks of exacerbations to develop. Further studies on Ab-mediated proteolysis may provide a supplementary tool for predicting demyelination

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Molecular Biomarkers & Diagnosis.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Molecular Biomarkers & Diagnosis
  • SubjectGenetics & Molecular Biology
  • SubjectPathology & Lab Medicine
  • BylineArticles whose byline prints “Sergey Suchkov”
  • BylineArticles whose byline prints “Noel Rose”
  • BylineArticles whose byline prints “Aleks Gabibov”